“Long-Term Safety of Sonidegib in Basal Cell Carcinoma: 30-Month Results from the BOLT Trial” (2018) SKIN The Journal of Cutaneous Medicine, 2(S1), p. S47. doi:10.25251/skin.2.supp.47.